Product Description
a new anti-emetic for the suppression of postanaesthetic nausea and vomiting (Sourced from: https://pubmed.ncbi.nlm.nih.gov/5325244/)
Mechanisms of Action: DR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bosnia | Chile | Croatia | Czech | India | Ireland | Italy | New Zealand | Pakistan | Peru | Poland | Russia | Slovakia | Slovenia | Sweden | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Immungenetics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
IG-TEP-001 | P2 |
Unknown Status |
Alzheimer Disease |
2027-12-31 |